Results from the Phase III CALGB/SWOG 80405 Trial
Richard Goldberg, MD, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting.
Richard Goldberg, MD, Physician-in-Chief at Ohio State’s Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (mCRC).
<<<
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
